Small Cell Lung Cancer: Molecular Pathology and Emerging Therapeutics

Small cell lung cancer (SCLC) makes up about 15% of all lung cancer cases and stands out for its aggressive nature. It grows rapidly, spreads early, and unfortunately, often comes with a poor outlook (known as prognosis in medicine). Unlike non-small cell lung cancer (NSCLC), which refers to other subtypes of lung cancer and generally progresses more slowly as a rule of thumb, SCLC is widely feared because of its high rate of cell division which helps it rapidly develop resistance to standard treatments like chemotherapy drugs. However, recent breakthroughs in molecular oncology have offered new hope and provided us with new insights into how this disease develops and how we might treat it more effectively. Hopefully, this scourge can  be more effectively treated in the next few years.

The Science Behind SCLC: How It Starts and Grows

The primary risk factor for SCLC is long-term tobacco use, as studies have consistently demonstrated a strong link between smoking and the development of this cancer. On a genetic level, SCLC is caused by several key mutations in genes that would normally have stopped it from progressing, most notably the inactivation of key tumor suppressor genes.

Notably, nearly all SCLC tumors show mutations in two crucial tumor suppressor genes: TP53 and RB1. These genes help control how cells grow and when they die, acting as gatekeepers that prevent damaged cells from becoming malignant. When they’re not functioning properly, cells can avoid this critical defense mechanism and begin to multiply uncontrollably, forming aggressive tumors (George et al., 2015).

SCLC typically arises from neuroendocrine cells, but they often show amplifications of the MYC gene on top of that, which fuels the cancer’s rapid growth. These changes also influence the degree of neuroendocrine differentiation—meaning the phenotype (or observed traits) of the cancer cells can become more or less like typical neuroendocrine cells. Mutations like these contribute to the tumor’s ability to spread quickly and metastasize (or spread) which allows them to affect distant parts of the body (Rudin et al., 2019). Oftentimes the brain is invaded by SCLC, maybe due to their neuroendocrine properties that help them adapt to the new microenvironment.

Clinical Features: How SCLC Presents and Progresses

One of the most troubling and frightening aspects of SCLC is how fast it divides, metastasizes, kills. Here’s the scary part: by the time doctors catch it, SCLC has often already made its move—spreading to other organs before anyone even knows it’s there. These tumors grow at breakneck speed,doubling in size in under a month, way faster than most other lung cancers (Byers & Rudin, 2015). That’s how it ends up in the brain, liver, bones, or adrenal glands so quickly, bringing on all kinds of symptoms depending on where it sets up shop.

What makes SCLC even trickier is how it can throw off the body’s whole system. Because of its neuroendocrine nature, it can lead to odd, hard-to-pin-down conditions—like SIADH or Lambert-Eaton syndrome—that aren’t directly caused by the tumor itself. These paraneoplastic syndromes (symptoms caused by a cancer-related immune or hormonal response, not by the direct presence of the tumor itself) often confuse things, making diagnosis tougher and treatment harder not just for doctors, but for patients and their families, who are already dealing with enough (Graus et al., 2010).

SCLC is generally divided into two stages:

• Limited-stage (LS-SCLC): The cancer is confined to one lung and nearby lymph nodes and can be treated with localized therapy.

• Extensive-stage (ES-SCLC): The cancer has spread further, often seeding secondary tumours beyond the chest.

Sadly, the outlook for small cell lung cancer (SCLC) is still bleak—especially for those with extensive-stage disease, where survival beyond five years remains rare, under 7% (Kalemkerian et al., 2018).

For a long time, the go-to treatment has been chemotherapy, usually with platinum-based drugs. These can work well at first, but unfortunately, the cancer often becomes resistant pretty fast.

That said, things are beginning to shift. There are now some promising new therapies in the works.

You’d think with all the mutations in SCLC tumors, the immune system would catch on sooner—and actually, that’s kind of the point behind some of the newer treatments. Drugs like atezolizumab and nivolumab, called checkpoint inhibitors, try to unmask the cancer so the immune system can go after it (Hellmann et al., 2019).

Another weakness lies in how poorly SCLC cells repair their own DNA. That’s where PARP inhibitors like olaparib come in—they disrupt the repair process even further, which can lead to the cancer cells breaking down (Owonikoko et al., 2020).

There's also a newer approach targeting a specific protein called DLL3. This protein is found on SCLC cells but not on most normal ones. Drugs like rovalpituzumab tesirine use an antibody to seek out DLL3 and deliver a toxic hit directly to the tumor, sparing healthy tissue in the process (Saunders et al., 2015).

Even with all these treatments on the table, SCLC is still a grave danger. It grows fast, spreads even faster, is notoriously difficult to catch early and even harder to treat effectively. That’s why so many scientists are still in the lab, trying to figure it out—what makes it tick, and more importantly, how to stop it. Hopefully, something sticks soon. Patients can’t afford to wait.

References

• Byers, L. A., & Rudin, C. M. (2015). Small cell lung cancer: Where do we go from here? Cancer Discovery, 5(12), 1336-1350.

• Gardner, E. E., et al. (2017). Histone methylation drives SCLC progression. Nature Communications, 8, 14487.

• George, J., et al. (2015). Comprehensive genomic profiles of small cell lung cancer. Nature, 524(7563), 47-53.

• Graus, F., et al. (2010). Paraneoplastic neurological syndromes. Lancet Neurology, 9(3), 263-275.

• Hellmann, M. D., et al. (2019). Nivolumab plus chemotherapy for SCLC. New England Journal of Medicine, 381(23), 2220-2229.

• Kalemkerian, G. P., et al. (2018). Staging and treatment guidelines for small cell lung cancer. Journal of Thoracic Oncology, 13(6), 801-819.

• Owonikoko, T. K., et al. (2020). PARP inhibition in small cell lung cancer. Cancer Cell, 38(3), 404-416.

• Rudin, C. M., et al. (2019). MYC in small cell lung cancer. Science Translational Medicine, 11(510), eaau4823.

• Saunders, L. R., et al. (2015). DLL3-targeted therapy for small cell lung cancer. Nature, 528(7582), 349-353.

Image Credit

•